Slingshot members are tracking this event:
Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
Do you think this event is important to the companies below? How will it affect their stock price?
Other key results from ODYSSEY ESCAPE, which will be concurrently published in the European Heart Journal, include: Ninety-three percent of patients treated with Praluent experienced at least a 50 percent reduction in their apheresis procedures (p greater than 0.0001). Throughout the trial, patients treated with Praluent experienced significant reductions in their LDL cholesterol starting at week 6 (55 percent greater reduction compared to placebo), and lasting until the trial ended, at week 18 (46 percent greater reduction compared to placebo) (p less than 0.0001). A similar proportion of patients experienced adverse events (AEs) in both the Praluent and placebo groups (76 percent both groups). The most common AEs (occurring in at least 5 percent of the Praluent group) were: fatigue (15 percent Praluent; 10 percent placebo), nasopharyngitis (10 percent Praluent; 10 percent placebo), diarrhea (10 percent Praluent; 0 percent placebo), myalgia (10 percent Praluent; 5 percent placebo), upper respiratory infection (7 percent Praluent; 19 percent placebo), headache (7 percent Praluent; 5 percent placebo), arthralgia (7 percent Praluent; 10 percent placebo), and back pain (5 percent Praluent; 10 percent placebo).
Slingshot Insights Explained
Aug 29, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Praluent, Alirocumab, Ldl Apheresis, Esc Congress 2016